The purpose of this study is to provide access to Ga-68-PSMA-11 PET for evaluation of male
veterans with newly diagnosed or biochemically recurrent prostate cancer. All patients will
receive conventional imaging (MRI, CT, and/or a molecular imaging bone scan) as well as
Ga-68-PSMA-11 PET in order to evaluate the utility of diagnostic testing in patients with
positive PSA status, a comparison of results from conventional imaging and PSMA PET imagining
will be performed.
Phase:
Phase 3
Details
Lead Sponsor:
Timothy Hoffman
Collaborators:
Harry S. Truman Memorial Veterans' Hospital Telix Pharmaceuticals, Ltd University of Missouri-Columbia